Segal Cancer Centre
Message from the Director
Oncology Interdisciplinary Teams
New Referrals
Cancer Treatment Unit
Oncology Nursing
Oncology Pharmacy
Radiation Oncology
Psychosocial Oncology Program
Hope & Cope
Cancer Prevention Center
Cancer Nutrition Rehabilitation Center
Oncology and Aging Program
Palliative Care
Adolescent and Young Adult Oncology Program
Education and Training
Physicians
Molecular Pathology
Research
Peter Brojde Lung Cancer Centre
Segal Cancer Centre News
Handling of Body Fluids
Links
Mark Basik, MD

Positions
Attending Surgical Oncologist, Sir Mortimer B. Davis-Jewish General Hospital
Assistant Professor, Department of Oncology, McGill University

Medical School
McGill University, Montreal, QC

Internship/Residency
St. Mary’s Hospital, McGill University, Montreal, QC
Université de Montréal, Montreal, QC
Montreal General Hospital, McGill University, Montreal, QC

Fellowship
Roswell Park Cancer Institute, Buffalo, NY                    

Clinical Specialties
Surgical Oncology; Breast Cancer; Colon Cancer.

Research Interests
Breast Cancer; Colon Cancer; Tumour Banks; Cancer Genomics; Diagnostic Tumour Markers; Tissue Microarrays; Gene Expression; siRNA; Chemokines.

Dr. Mark Basik joined the Sir Mortimer B.Davis-Jewish General Hospital in 2003 as an Attending Surgical Oncologist. Previously he was an Attending Surgical Oncologist at Hôtel-Dieu de Montréal for seven years before spending 18 months as a Visiting Investigator at the National Human Genome Research Institute, NIH in Bethesda, Maryland, and 6 months as a Medical Researcher in the Translational Genomics Research Institute, Cancer Drug Development Laboratory in Gaithersburg, MD.
 
Dr. Basik’s research interests focus on gene expression and DNA changes in breast and colon cancers. Using modern microarray technology, his group is investigating the relationship between DNA copy number changes and gene expression across the genome in both cell lines and primary tumours. The goal is to find genes that are overexpressed as well as amplified in these cancers. These genes will then be candidate targets for novel anti-cancer therapies. They will be functionally validated using small interfering RNA approaches, and clinically validated using tissue microarrays constructed at the laboratory. His group is also involved in the discovery of new diagnostic markers in the same two tumours. They have a special focus on markers of breast cancer metastasis, specifically chemokines and their receptors. They are also investigating mechanisms of resistance to novel biologics such as herceptin. Finally, Dr. Basik’s group is part of the FRSQ Reseau de Cancer axe cancer du sein/ovaire, and as such are actively participating in a province-wide breast tumour banking as well as placing primary breast tumour into culture. A particular interest is in the stromal-epithelial interactions active in breast tumour biology.

Additional information on Dr. Mark Basik.